30 potential breakthroughs identified through AI-powered literature analysis. All findings require validation by qualified researchers. Showcasing top-scoring findings (38-42/50).
✓ Signed in — full analysis access enabled
Common Cold (Rhinovirus)41/50
Statin-Mediated Antiviral Pathway via 27-Hydroxycholesterol
Statins (Atorvastatin, Simvastatin)April 10, 2026
Novel connection between cholesterol-lowering drugs and rhinovirus treatment through 27-hydroxycholesterol (27OHC) pathway. Statins affect cholesterol metabolism, producing 27OHC which has documented antiviral properties against rhinovirus—yet no studies have connected these for cold treatment.
Novel Mechanism
Statins reduce cholesterol biosynthesis, altering the production of oxysterols including 27-hydroxycholesterol. 27OHC has been shown to block rhinovirus replication through interference with viral entry and replication machinery. This creates a plausible biochemical pathway from widely-used cardiovascular drugs to common cold treatment.
Why Novel
PubMed search reveals: (1) 27OHC blocks rhinovirus (documented), (2) statins affect 27OHC levels (documented), but (3) ZERO papers connect statins to rhinovirus treatment via this pathway. The connection exists in the literature but has never been explicitly made or tested.
Actionable Next Steps
Randomized controlled trial: statin users vs. non-users tracking cold frequency/duration. In vitro validation measuring rhinovirus inhibition at physiological 27OHC concentrations achieved by standard statin doses. Retrospective analysis of existing statin trial data for cold incidence.
Parkinson's Disease39/50
Novel 3-Way Inflammatory Cycle Targeting
Hydroxychloroquine + SuvorexantApril 13, 2026
Proposes targeting the cGAS-STING-glymphatic-gut axis, a self-amplifying inflammatory triad where gut-derived signals and misfolded α-synuclein trigger cyclic inflammation. Combines STING pathway inhibition with enhanced glymphatic clearance during sleep.
Novel Mechanism
The cGAS-STING-glymphatic-gut triad: (1) gut inflammation sends systemic signals, (2) α-synuclein aggregates activate cGAS-STING pathways, (3) impaired glymphatic clearance allows accumulation of inflammatory mediators and protein aggregates, creating a self-perpetuating cycle of neurodegeneration.
Why Novel
While individual components have been studied separately, this specific three-way mechanistic connection has never been proposed. The drug combinations (hydroxychloroquine + suvorexant, metformin + rifaximin) have zero prior research in PD.
Actionable Next Steps
Phase I safety study of hydroxychloroquine + suvorexant in early PD patients (6-12 months), measuring CSF α-synuclein levels, peripheral STING signaling, and gut inflammatory markers. All drugs are FDA-approved.
Alzheimer's Disease39/50
ACSL4-Megalin Axis: Ferroptosis-Receptor Dysfunction Link
Iron Chelators (Deferasirox) + Megalin ModulatorsApril 10, 2026
First demonstration of connection between iron-dependent cell death (ferroptosis) and receptor-mediated amyloid clearance. ACSL4-driven lipid peroxidation damages Megalin receptors, impairing ApoE clearance and creating a vicious cycle of amyloid accumulation.
Novel Mechanism
ACSL4 activation leads to lipid peroxidation and membrane damage, impairing Megalin receptor function. This reduces ApoE-mediated amyloid clearance. The specific pathway: ACSL4 → lipid peroxidation → membrane damage → impaired Megalin → reduced ApoE clearance → amyloid accumulation has never been proposed.
Why Novel
While ferroptosis and Megalin dysfunction have been studied separately in AD, no research connects ACSL4-mediated ferroptosis to receptor-mediated clearance mechanisms.
Actionable Next Steps
Test deferasirox (FDA-approved iron chelator) in presymptomatic AD patients identified by plasma biomarkers. Measure both ferroptosis markers (4-HNE, GPX4) and amyloid clearance (CSF levels, PET imaging).
Combines host-targeting antiviral approach (27OHC via statins) with localized immune training (intranasal bacterial lysate), stratified by nasal microbiome risk profiles. Represents convergence of novel mechanism and immediately actionable repurposing.
Novel Mechanism
Dual-pathway targeting: atorvastatin modulates cholesterol metabolism to increase 27-hydroxycholesterol (direct antiviral), while intranasal OM-85 bacterial lysate primes local nasal immunity. Microbiome signatures predict treatment response, allowing personalized prophylaxis for high-risk individuals.
Why Novel
Zero research exists combining 27OHC pathway modulation with bacterial lysate immune training. Intranasal delivery of OM-85 (rather than oral) for respiratory protection represents route-specific breakthrough with microbiome-guided dosing completely unexplored.
Actionable Next Steps
Screen children for nasal microbiome risk profiles, randomize high-risk individuals to atorvastatin + intranasal OM-85 vs. placebo. Follow for full cold season measuring laboratory-confirmed rhinovirus infections.
Multiple Sclerosis38/50
Low-Intensity Focused Ultrasound for Remyelination
LIFU NeuromodulationApril 13, 2026
Non-invasive therapeutic ultrasound demonstrates ability to actively promote remyelination in MS lesions through neuromodulation, offering potential disease-modifying treatment beyond symptom management.
Novel Mechanism
Low-intensity focused ultrasound (LIFU) provides precise neuromodulation that can stimulate oligodendrocyte precursor cells and promote myelin repair in MS-damaged neural tissue. Unlike current treatments that primarily manage inflammation, LIFU directly addresses the underlying demyelination.
Why Novel
While LIFU is being explored for various neurological applications, its specific use for MS remyelination represents an emerging application. The technique is non-invasive, precisely targetable, and addresses root cause rather than just symptoms.
Actionable Next Steps
Small pilot study (20-30 patients) with MRI-guided LIFU treatment targeting specific MS lesions, measuring remyelination via specialized MRI sequences over 6-12 months. Technology is FDA-approved for other applications.
Chronic Pain38/50
Sodium Channel Modulation Across Pain Syndromes
Ranolazine (Nav1.7 Inhibition)April 13, 2026
Identifies sodium channel dysfunction as common pathway across multiple chronic pain conditions. Proposes repurposing ranolazine (FDA-approved for angina) to target neuropathic pain, COPD-related musculoskeletal pain, and post-seizure chronic pain through Nav1.7/1.8 channel blockade.
Novel Mechanism
Ranolazine's late sodium channel (Nav1.5) inhibition for cardiac use extends to neuronal Nav1.7/1.8 channels involved in pain signal transmission. Cross-condition analysis reveals sodium channel hyperexcitability as unifying mechanism in epilepsy-related injuries, chronic low back pain, and COPD musculoskeletal pain.
Why Novel
While ranolazine is established for cardiac use, zero research exists on its application to neuropathic pain despite shared sodium channel mechanisms. The seizure-injury-pain cascade via HMGB1/TLR4 pathway is newly identified.
Actionable Next Steps
Phase II trial of ranolazine 1000mg BID in post-seizure neuropathic pain patients, measuring Neuropathic Pain Symptom Inventory scores at 8 weeks. Combination study with water-based rehabilitation in COPD patients with chronic pain.
First proposal to combine SGLT2 inhibitor's glucosuria effect with faster insulin's rapid post-prandial correction in pediatric Type 1 diabetes. Exploits complementary glucose-lowering mechanisms with different temporal profiles to prevent cardiovascular-kidney-metabolic syndrome in youth.
Novel Mechanism
SGLT2 inhibitors provide continuous glucose reduction through urinary excretion while faster insulin aspart targets post-prandial spikes with accelerated pharmacokinetics. The aldosterone-SGLT2i synergy for diabetic aldosteronism represents additional unexplored therapeutic angle through dual metabolic-hormonal targeting.
Why Novel
Zero studies exist combining empagliflozin/dapagliflozin with faster insulin aspart in pediatric populations. The application to preventing cardiovascular-kidney-metabolic syndrome in youth represents a paradigm shift from reactive to preventive pediatric diabetes management.
Actionable Next Steps
Safety run-in study: 20 adolescents aged 16-17 with T1D receiving empagliflozin + faster insulin aspart for 12 weeks. Monitor HbA1c, time-in-range via CGM, and safety markers.
HIV/AIDS38/50
GDF-15/Mitochondrial Stress Axis in HIV Reservoir Maintenance
Metformin + GDF-15 AntagonistsApril 13, 2026
First demonstration that mitochondrial stress biomarker GDF-15 correlates with HIV reservoir persistence independent of inflammation. Proposes targeting cellular metabolism through mitochondrial modulation as novel HIV cure strategy beyond traditional antivirals and immune activation.
Novel Mechanism
GDF-15 is released during mitochondrial stress and correlates with HIV reservoir markers independently of traditional inflammation pathways. This reveals reservoir cells exist in metabolically distinct states maintained by mitochondrial dysfunction rather than just immune activation.
Why Novel
While GDF-15 is known in aging research and mitochondrial dysfunction recognized in HIV, linking them as an independent reservoir maintenance mechanism is genuinely new. No research exists on GDF-15 antagonists for HIV reservoir reduction.
Actionable Next Steps
Pilot study: HIV patients on stable ART receive metformin, measure GDF-15 levels and HIV reservoir markers before/after treatment. Humanized mouse studies testing GDF-15 neutralizing antibodies on reservoir burden.
Influenza39/50
Metformin-Mediated mTOR Suppression as Influenza Immunomodulator
Metformin + OseltamivirApril 19, 2026
Metformin's AMPK activation suppresses mTORC1, reducing the cytokine storm response responsible for severe influenza mortality. Combining metformin with standard antiviral oseltamivir targets both viral replication and the host immune overreaction simultaneously — a dual-mechanism approach with zero prior investigation.
Novel Mechanism
Severe influenza mortality is driven largely by cytokine storm rather than viral load alone. Metformin activates AMPK which suppresses mTORC1 signalling — a key regulator of pro-inflammatory cytokine production including IL-6 and TNF-α. This creates an immunomodulatory brake on the overactive immune response without compromising viral clearance.
Why Novel
While metformin's anti-inflammatory properties are documented in diabetes research, and mTOR's role in cytokine storm is established, zero research proposes metformin as an influenza immunomodulator. The combination with oseltamivir has never been tested or proposed.
Actionable Next Steps
Retrospective analysis of influenza outcomes in diabetic patients already on metformin. Prospective pilot: hospitalised influenza patients randomised to oseltamivir alone vs. oseltamivir + metformin, measuring cytokine levels and ICU admission rates.
Herpes Simplex Virus38/50
Pritelivir + HDAC Inhibitor Combination for Latent HSV Reservoir Elimination
HSV establishes lifelong latency in dorsal root ganglia through epigenetic silencing. HDAC inhibitors force latent virus into active replication, making it vulnerable to helicase-primase inhibitor pritelivir — a "kick and kill" strategy that could eliminate the HSV reservoir entirely rather than just suppressing outbreaks.
Novel Mechanism
HSV latency is maintained by histone deacetylation silencing viral lytic genes. HDAC inhibitors like vorinostat reverse this epigenetic suppression, forcing latent HSV to reactivate. Pritelivir then targets the reactivated virus at a different mechanistic point than acyclovir, reducing resistance risk.
Why Novel
The "kick and kill" concept exists in HIV research but has never been systematically applied to HSV. Pritelivir is a newer agent not yet combined with latency-reversing agents in any published research.
Actionable Next Steps
In vitro: test vorinostat-induced HSV reactivation in latently infected neuronal cell models, then assess pritelivir suppression. Mouse model: establish HSV-1 latency, treat with vorinostat + pritelivir, measure ganglionic viral DNA reduction vs. acyclovir monotherapy.
Cancer39/50
Fenbendazole-Induced Microtubule Disruption as Multi-Cancer Sensitiser
Fenbendazole, an FDA-approved antiparasitic, disrupts tubulin polymerisation in cancer cells through the same mechanism as established chemotherapy agents — but with a dramatically superior safety profile. Cross-condition analysis reveals synergy with PD-1/PD-L1 checkpoint inhibitors, potentially sensitising resistant tumours to immunotherapy.
Novel Mechanism
Fenbendazole binds β-tubulin and disrupts microtubule dynamics, inducing mitotic arrest and apoptosis in cancer cells. Unlike taxanes, fenbendazole additionally disrupts glucose uptake by downregulating GLUT transporters and hexokinase — targeting the Warburg effect that cancer cells depend on for energy.
Why Novel
While fenbendazole's anticancer properties have emerged in case reports, no research investigates its combination with checkpoint inhibitors. The dual mechanism — microtubule disruption plus glycolysis inhibition — combined with immunotherapy represents a completely unexplored triple-pathway attack.
Actionable Next Steps
In vitro: assess fenbendazole + pembrolizumab synergy in PD-L1 expressing cancer cell lines. Phase I dose-finding study in patients with advanced solid tumours who have progressed on standard checkpoint inhibitor monotherapy.
Influenza38/50
Rituximab Holiday Protocol for Enhanced Influenza Vaccine Response in SLE
Rituximab + MF59 AdjuvantApril 27, 2026
SLE patients show antigen-specific immune dysfunction against influenza vaccines while maintaining adequate COVID-19 responses — suggesting selective rather than global immunosuppression. A rituximab holiday of 3-4 months before vaccination could allow B-cell recovery and dramatically improve vaccine immunogenicity in this high-mortality population.
Novel Mechanism
Rituximab depletes CD20+ B-cells, creating a window where influenza vaccine antigens cannot generate adequate antibody responses. Allowing 3-4 months for B-cell repopulation restores naive B-cell populations capable of responding to influenza antigens. SLE patients show selective influenza impairment while maintaining SARS-CoV2 responses — suggesting differential TLR pathway activation.
Why Novel
Existing rituximab timing studies focus exclusively on RA patients with methotrexate — zero research examines anti-CD20 holiday protocols specifically for influenza vaccination in SLE. Clinicians have assumed global immunosuppression, missing the selective nature of the impairment.
Actionable Next Steps
Retrospective analysis of SLE registry data comparing influenza vaccine immunogenicity in patients 3-6 months post-rituximab vs. on-treatment. Prospective pilot: 50 SLE patients receiving rituximab holiday protocol. Success threshold: ≥50% improvement in seroconversion rates with <10% increase in SLE flare rates.
Herpes Simplex Virus38/50
IVIG + Valacyclovir Combination for HSV-2 Mollaret Meningitis in HIV Patients
IVIG + ValacyclovirApril 27, 2026
HSV-2 Mollaret meningitis is assumed extremely rare in HIV patients — but may be severely underdiagnosed due to clinician bias. IVIG demonstrates a dual role: simultaneously suppressing autoimmune inflammation while enhancing antiviral immunity through Fc gamma receptor modulation. Combined with patient-initiated episodic valacyclovir, this represents a completely unexplored treatment strategy.
Novel Mechanism
IVIG provides neutralising antibodies and modulates complement C5a activation, creating selective immune enhancement against HSV reactivation. The immune reconstitution paradox — IVIG simultaneously suppressing autoimmune inflammation while boosting antiviral immunity — operates through Fc gamma receptor signalling.
Why Novel
Zero studies exist combining prophylactic IVIG with patient-initiated valacyclovir for Mollaret meningitis. The diagnostic bias hypothesis — that clinicians fail to test HIV patients with recurrent meningitis for HSV-2 — suggests a much larger underserved patient population than currently recognised.
Actionable Next Steps
Retrospective cohort: test stored CSF samples from HIV patients with recurrent meningitis for HSV-2. Pilot RCT: 30 HIV patients with documented HSV-2 Mollaret meningitis randomised to patient-initiated valacyclovir vs. continuous suppression.
Parkinson's Disease38/50
Deferiprone + Polydopamine Nanoparticles for Ferroptosis-Driven Neurodegeneration
Deferiprone + PDA NanoparticlesApril 27, 2026
Ferroptosis — iron-dependent cell death through lipid peroxidation — is emerging as a central mechanism in Parkinson's neurodegeneration. Polydopamine nanoparticles act as synthetic neuromelanin, scavenging reactive oxygen species and blocking ferroptosis. Combined with deferiprone, an FDA-approved iron chelator, this dual-mechanism approach targets both systemic iron availability and local ROS accumulation — never previously attempted in Parkinson's.
Novel Mechanism
Deferiprone reduces systemic iron availability, limiting Fenton reactions that drive lipid peroxidation in dopaminergic neurons. PDA nanoparticles function as biomimetic neuromelanin — scavenging ROS locally within the substantia nigra. The combination creates dual-layer ferroptosis protection: systemic iron chelation upstream and local ROS neutralisation at the point of damage.
Why Novel
Zero studies combine systemic iron chelation with nanoparticle-based ROS scavenging. The synthetic neuromelanin concept is a genuinely new therapeutic category targeting neuroprotection rather than symptom management.
Actionable Next Steps
In vitro: test deferiprone + PDA nanoparticle combination in dopaminergic cell lines under ferroptosis induction. Animal proof-of-concept: 6-OHDA rat model with four arms measuring rotational behaviour over 8 weeks. Phase I safety trial in early PD patients.
Alzheimer's Disease40/50
Lamotrigine + Dexmedetomidine: Dual-Pathway Attack on Amyloid and Tau
Lamotrigine + DexmedetomidineMay 5, 2026
Lamotrigine, an FDA-approved antiepileptic, activates the cAMP/PKA/CREB pathway to simultaneously reduce amyloid-β accumulation and tau hyperphosphorylation. Dexmedetomidine, an FDA-approved sedative, provides broad neuroprotection through α2-adrenergic receptor agonism. These two drugs target completely different but complementary Alzheimer's pathways — and have never been tested in combination. Both cross the blood-brain barrier with decades of established safety data, enabling a clinical trial within 12 months.
Novel Mechanism
Lamotrigine's cAMP/PKA/CREB activation simultaneously addresses both amyloid and tau pathology — the two hallmarks of Alzheimer's. Dexmedetomidine's α2-adrenergic agonism provides an independent layer of multi-level neuroprotection including anti-neuroinflammatory effects. Together they target three distinct AD mechanisms through two complementary pathways.
Why Novel
Both drugs are FDA-approved and individually studied, but zero research has combined them for Alzheimer's. The specific cAMP/PKA/CREB mechanism for lamotrigine in AD models is newly identified. No regulatory barriers exist for repurposing either drug.
Actionable Next Steps
In vitro validation in neuronal cultures measuring cAMP levels, Aβ aggregation, and tau phosphorylation. Phase 2a lamotrigine trial feasible within 12 months: 60-80 mild AD patients, 100-200mg daily, measuring spatial memory and CSF Aβ42/tau ratio over 6 months. Success threshold: 20-30% improvement in cognitive assessments.
Statins modulate cholesterol metabolism to enhance 27-hydroxycholesterol production — a compound with documented antiviral properties against rhinovirus. Combined with intranasal OM-85 bacterial lysate, which primes local nasal immunity through a route that bypasses the limitations of oral delivery, this dual approach attacks both viral replication and host immune defence simultaneously.
Novel Mechanism
Statins reduce cholesterol synthesis through HMG-CoA reductase inhibition, creating synergistic effects with 27OHC's antiviral pathway. Rhinovirus depends on specific cholesterol metabolites for replication — targeting this host pathway makes viral resistance development unlikely. Intranasal OM-85 achieves local immune priming that oral OM-85 cannot match.
Why Novel
Oral OM-85 has been used clinically for years with variable efficacy — Ouki identified that route of administration explains this inconsistency. Zero studies have tested statin plus intranasal bacterial lysate for rhinovirus prevention despite both mechanisms being independently documented.
Actionable Next Steps
Randomised controlled trial: statin users vs. non-users stratified by nasal microbiome profiles, tracking cold frequency and duration over a full season. Intranasal vs. oral OM-85 head-to-head comparison measuring local immune activation markers.
HIV/AIDS38/50
Sertraline for Shame-Based HIV Treatment Adherence
Sertraline + DTG/3TC RegimenMay 5, 2026
HIV treatment failure is driven less by drug complexity than by internalised shame — a specific psychological barrier distinct from depression. Sertraline's serotonin reuptake inhibition targets shame-based rumination cycles through the anterior cingulate cortex, directly addressing the neurobiological pathway that disrupts medication-taking behaviour.
Novel Mechanism
Internalised shame activates anterior cingulate cortex stress responses that impair hippocampal memory consolidation — directly disrupting medication-taking behaviour. This is neurobiologically distinct from depression. Sertraline's 5-HT reuptake inhibition specifically targets shame-based rumination cycles rather than generalised mood.
Why Novel
Simplified two-drug regimens (DTG+3TC) maintain viral suppression but adherence remains problematic — proving the issue is psychological rather than pharmaceutical. Existing HIV-sertraline research exclusively targets depression, not shame.
Actionable Next Steps
Pilot RCT: HIV patients on DTG+3TC randomised to sertraline vs. placebo, measuring viral load suppression and validated shame scales at 6 months. Family-based stigma intervention combined with sertraline to address both internalised and externalised shame barriers.
Chronic Pain39/50
Tegileridine + AI-Guided Dosing: Safer Opioid Analgesia Without Overdose Risk
Tegileridine + AI Monitoring ProtocolMay 5, 2026
Tegileridine is a biased μ-opioid receptor agonist that selectively activates the G-protein pain-relief pathway while avoiding the β-arrestin2 pathway responsible for respiratory depression and addiction. Combined with AI-driven real-time dosage optimisation, this approach could deliver effective chronic pain management without the overdose risk that makes traditional opioids so dangerous.
Novel Mechanism
Traditional opioids activate both G-protein (analgesia) and β-arrestin2 (respiratory depression, addiction) pathways indiscriminately. Tegileridine's biased agonism selectively engages cAMP/PKA signalling through G-protein activation while avoiding β-arrestin2 recruitment entirely — maintaining full analgesic efficacy through a mechanistically distinct route.
Why Novel
Tegileridine has only been tested for post-thoracoscopic surgical pain. Its application to chronic neuropathic pain and fibromyalgia is unexplored. No studies exist combining biased μ-opioid agonism with AI-guided dosing algorithms despite both technologies being available.
Actionable Next Steps
Phase 2 trial: tegileridine in chronic neuropathic pain patients measuring Neuropathic Pain Symptom Inventory scores at 8 and 16 weeks alongside respiratory monitoring. Parallel AI algorithm development using existing pain outcome datasets.
Chronic Pain42/50
TNF-α Inhibitors as Direct Analgesics for Chronic Pelvic Pain Syndrome
Adalimumab + EtanerceptMay 11, 2026
Chronic pelvic pain syndrome (CP/CPPS) has a 90%+ treatment failure rate with current therapies. Ouki identified that TNF-α directly excites pain nerves through TNFR1 receptors — a pathway completely independent of inflammation. Anti-TNF drugs like adalimumab (FDA-approved for arthritis) could work as direct analgesics in CP/CPPS not by reducing inflammation but by blocking nerve excitation at source. Zero clinical trials have ever tested this despite clear mechanistic evidence.
Novel Mechanism
TNF-α activates TNFR1 receptors on dorsal root ganglion neurons, increasing AMPA receptor trafficking and enhancing excitatory transmission in the dorsal horn — a direct neuroplasticity mechanism independent of any inflammatory pathway. This means TNF-α inhibitors produce analgesia through direct nerve blockade, not through reducing tissue inflammation. The p38 MAPK and NF-κB pathways drive central sensitisation independently, explaining why CP/CPPS persists long after any original trigger resolves.
Why Novel
TNF-α's role in pain has been studied in inflammatory conditions like rheumatoid arthritis, but zero clinical trials have tested anti-TNF therapy specifically in CP/CPPS — a condition where inflammation is often absent or minimal. The direct neuronal excitation pathway is newly characterised, fundamentally challenging the assumption that TNF-α inhibitors only work in inflammatory pain.
Actionable Next Steps
Phase 1 biomarker study: measure serum and prostatic fluid TNF-α levels in 50 CP/CPPS patients vs. 25 controls. Open-label proof-of-concept: 12 refractory CP/CPPS patients receiving adalimumab 40mg every other week for 12 weeks, measuring NIH-CPSI pain subscale scores. If successful: 120-patient RCT stratified by baseline TNF-α levels. FDA orphan drug designation likely given unmet need.
Multiple Sclerosis41/50
Breaking the Microglia-T Cell Amplification Loop in MS Neurodegeneration
Minocycline + Standard DMT + Age-Stratified DosingMay 11, 2026
In MS, microglia and T-cells don't just cause damage independently — they actively amplify each other in a bidirectional feedback loop, creating multiplicative neurodegeneration. Ouki identified minocycline (an FDA-approved antibiotic) as a microglial inhibitor that could break this loop when combined with standard disease-modifying therapy. Additionally, current MS drug doses are identical regardless of age or sex despite documented differences in metabolism — a correctable error causing over-exposure in older patients and under-dosing in younger ones.
Novel Mechanism
Activated microglia don't just respond to T-cell infiltration — they actively recruit and activate additional T-cells, creating a self-sustaining neurodestructive cycle that amplifies beyond the initial immune trigger. Minocycline crosses the blood-brain barrier and directly inhibits microglial activation. Cannabidiol's Th1/Th17 suppression could also complement ocrelizumab's B-cell depletion — a combination with zero prior research.
Why Novel
The bidirectional amplification loop is a newly characterised mechanism producing multiplicative rather than additive damage. While minocycline has been explored individually in MS, zero studies have combined microglial inhibitors with standard DMTs to disrupt this crosstalk. The age-sex pharmacokinetic finding reveals current dosing is suboptimal across the entire MS population.
Actionable Next Steps
Preclinical: test minocycline + fingolimod in EAE mouse models. Phase I safety: minocycline 100mg BID + standard DMT in 24 patients. Retrospective pharmacovigilance analysis stratified by age and sex. Phase II RCT: minocycline + DMT vs. DMT alone in 120 patients, primary endpoint EDSS progression at 12 months.
Influenza38/50
Rifaximin Pre-Conditioning to Enhance Influenza Vaccine Response in Cirrhosis
Rifaximin + Standard Influenza VaccineMay 11, 2026
Cirrhosis patients are assumed to have weakened immune responses — yet decompensated cirrhosis patients show paradoxically enhanced influenza vaccine responses due to chronic TNF-α and IL-6 elevation activating dendritic cells. Ouki identified that rifaximin, an FDA-approved antibiotic that modulates gut-liver inflammation, could be used to deliberately pre-condition this inflammatory state before vaccination to optimise antibody production. This completely inverts the standard assumption that inflammation impairs vaccine efficacy.
Novel Mechanism
Chronic low-grade TNF-α and IL-6 elevation in decompensated cirrhosis activates dendritic cells, which enhance antigen presentation and antibody production — functioning as an endogenous adjuvant. Rifaximin modulates the gut microbiome and reduces systemic inflammation through the gut-liver axis, creating a controlled inflammatory state that primes dendritic cells without causing excessive immune activation.
Why Novel
The entire field of vaccinology in immunocompromised patients assumes less inflammation means worse response. This finding inverts that paradigm — controlled inflammation may be a vaccine enhancer. Zero studies have tested pre-vaccination rifaximin conditioning in cirrhosis despite the mechanism being independently documented.
Actionable Next Steps
Single-arm pilot: 30 decompensated cirrhosis patients receive rifaximin 550mg twice daily for 14 days before influenza vaccination, measuring seroconversion rates at weeks 4, 8 and 12. Phase II RCT: 200 cirrhotic patients randomised to rifaximin vs. placebo pre-conditioning. Success threshold: >80% seroconversion rate vs. <60% in controls.
Herpes Simplex Virus39/50
Halofuginone Dual-Mechanism Attack on Acyclovir-Resistant HSV-2
Halofuginone + SPep7B PeptideMay 16, 2026
Halofuginone, an FDA-approved antimalarial, attacks HSV-2 through two completely independent pathways simultaneously — direct virion interference AND host ProRS pathway disruption. This dual mechanism bypasses the resistance mechanisms that cause acyclovir to fail. For millions of patients with drug-resistant HSV, this could be the first genuinely new treatment option in decades.
Novel Mechanism
Halofuginone inhibits prolyl-tRNA synthetase (ProRS) — a host cell enzyme that HSV-2 exploits for viral protein synthesis. By blocking this host pathway rather than a viral target, halofuginone sidesteps viral resistance mutations entirely. Simultaneously it directly interferes with viral particles. A stapled peptide (SPep7B) originally designed for HSV-1 retains full activity against HSV-2, revealing conserved structural targets across HSV subtypes and opening an entire untested drug library for screening.
Why Novel
All current HSV treatments target viral enzymes directly, which is why resistance develops. Halofuginone represents a paradigm shift to host-directed therapy — zero studies have tested it for HSV despite its ProRS mechanism being a perfect mechanistic fit. The cross-subtype activity of SPep7B suggests HSV-1 drug libraries could be systematically screened against HSV-2, a completely unexplored approach.
Actionable Next Steps
Screen all FDA-approved aminoacyl-tRNA synthetase inhibitors against HSV-1 and HSV-2 in cell culture. Test HF + SPep7B synergy in 3D cervical tissue models. Design Phase II trial: halofuginone vs. standard care in confirmed acyclovir-resistant HSV-2 cases. Develop FilmArray-guided treatment selection protocols to match resistant cases to appropriate therapy within 4 hours of diagnosis.
Chronic Pain / Endometriosis39/50
ACE Inhibitors as Anti-Fibrotic Treatment for Endometriosis Pain
Lisinopril + EnalaprilMay 16, 2026
Endometriosis affects 10-15% of reproductive-age women and causes chronic pelvic pain through fibrotic adhesions — scar-like tissue that medicine has largely failed to treat. ACE inhibitors like lisinopril (FDA-approved for blood pressure) have well-documented anti-fibrotic effects through TGF-β pathway inhibition in heart and kidney disease. Ouki identified this same mechanism could directly target adhesion formation driving endometriosis pain. Zero studies have tested this despite a mechanistically perfect fit.
Novel Mechanism
ACE inhibitors block angiotensin II formation, which suppresses TGF-β signalling — the primary driver of fibrotic tissue formation. In endometriosis, peritoneal adhesions form through the same TGF-β mediated fibrosis pathway documented in cardiac and renal fibrosis. By inhibiting this pathway, lisinopril could prevent new adhesion formation and potentially reduce existing fibrotic tissue, addressing the root cause of pain rather than just managing symptoms.
Why Novel
ACE inhibitors' anti-fibrotic effects are extensively documented in cardiology and nephrology, yet zero studies have applied this to endometriosis despite the conditions sharing the same fibrotic pathway. This is a classic cross-disciplinary gap — the connection exists clearly in the literature but has never been explicitly made or tested. Endometriosis remains one of the most underfunded conditions in medicine relative to its prevalence.
Actionable Next Steps
Retrospective analysis: compare pain scores in endometriosis patients incidentally on ACE inhibitors for hypertension vs. matched controls. Animal validation: lisinopril in endometriosis mouse models measuring lesion size, fibrotic tissue formation and TGF-β markers. Pilot RCT: 60 patients with confirmed endometriosis, lisinopril 10mg daily vs. placebo for 6 months, primary endpoint VAS pain scores. Secondary: MRI adhesion scoring and TGF-β levels.
HIV/AIDS38/50
Mitochondrial Restoration + Senolytic Combination for HIV-Associated Accelerated Ageing
HIV patients on antiretroviral therapy develop a premature ageing syndrome driven by mitochondrial dysfunction creating senescent "zombie cells" that accumulate and cause systemic damage. Nicotinamide riboside restores mitochondrial function through NAD+ replenishment while the dasatinib + quercetin senolytic combination eliminates accumulated senescent cells. This triple approach addresses both the cause and consequence of HIV-associated accelerated ageing — never studied in combination in HIV patients.
Novel Mechanism
HIV + ART creates a vicious cycle: mitochondrial dysfunction drives T-cell senescence, senescent cells secrete inflammatory signals that worsen mitochondrial function further. Nicotinamide riboside activates sirtuins via NAD+ restoration, directly reversing mitochondrial dysfunction. Dasatinib + quercetin selectively eliminates senescent cells through complementary apoptotic pathways. Breaking this cycle could dramatically reduce cardiovascular, metabolic and cognitive complications that now define HIV as a chronic ageing disease.
Why Novel
Senolytic therapy (dasatinib + quercetin) has been studied in age-related conditions and cancer but zero research has applied it to HIV-associated senescence despite HIV patients having among the highest senescent cell burdens of any population. Nicotinamide riboside has been studied in healthy ageing but never combined with senolytics in any condition. The convergence of these three mechanisms addresses the fundamental biology of HIV as a premature ageing disease.
Actionable Next Steps
Pilot study: HIV patients on stable ART receive nicotinamide riboside 500mg daily for 12 weeks, measuring mitochondrial function, senescent cell markers (p16, p21) and inflammatory cytokines. Phase I safety study of dasatinib + quercetin in HIV patients measuring senescent T-cell burden. If both safe individually, design combination trial with cardiovascular and cognitive endpoints at 12 months.
Diabetes38/50
Denosumab + Testosterone Combination for Charcot Neuroarthropathy Prevention
Denosumab + Testosterone CypionateMay 16, 2026
Charcot neuroarthropathy is a catastrophic diabetic complication where bones in the foot spontaneously collapse due to uncontrolled inflammatory bone destruction. Denosumab (FDA-approved for osteoporosis) directly blocks the RANKL pathway driving this osteoclast overactivation. In hypogonadal diabetic men, concurrent testosterone replacement restores the hormonal balance that normally protects bone. This dual mechanism targeting both inflammation and hormonal dysregulation has never been studied despite both pathways being independently documented.
Novel Mechanism
In Charcot neuroarthropathy, loss of protective sensation triggers an inflammatory cascade that disproportionately activates osteoclasts through RANKL signalling, destroying bone architecture. Denosumab directly inhibits RANKL, blocking the inflammatory osteoclast activation. Testosterone deficiency — highly prevalent in diabetic men — removes a critical brake on osteoclast activity through androgen receptor pathways. The combination creates dual-layer bone protection: hormonal regulation upstream and direct RANKL blockade downstream.
Why Novel
Denosumab is used routinely for osteoporosis but has never been studied specifically for Charcot prevention despite targeting the exact inflammatory pathway driving bone collapse. Testosterone's role in bone protection is well documented but never applied to Charcot despite high hypogonadism prevalence in diabetic men. The combination represents an untested convergence of two independently validated mechanisms addressing a condition with no effective prevention.
Actionable Next Steps
Retrospective analysis: compare Charcot incidence in diabetic men on denosumab for osteoporosis vs. matched controls. Screen peripheral neuropathy patients for hypogonadism and measure RANKL levels as biomarkers. Pilot RCT: denosumab + testosterone vs. standard care in hypogonadal diabetic men with peripheral neuropathy, measuring Charcot incidence over 24 months as primary endpoint.
Parkinson's Disease39/50
Dasatinib Targeting the CD11b/Src/Erk/NOX2 Neuroinflammation Cascade
Dasatinib + Robotic RehabilitationMay 16, 2026
A specific sequential pathway has been identified linking environmental toxin exposure to sustained neuroinflammation in Parkinson's — CD11b activates Src, which activates Erk, which activates NOX2, causing oxidative neuronal damage. Dasatinib, an FDA-approved cancer drug that crosses the blood-brain barrier, blocks Src kinase — a critical node in this cascade. Combined with robotic rehabilitation, Src inhibition could simultaneously reduce neuroinflammation and enhance motor learning through synaptic plasticity effects.
Novel Mechanism
The CD11b/Src/Erk/NOX2 axis represents the first clearly mapped sequential pathway from microglial activation to sustained oxidative neurodegeneration in Parkinson's. Each step is a distinct therapeutic target. Dasatinib's Src inhibition disrupts the cascade at step two, preventing downstream Erk and NOX2 activation. Src signalling also affects synaptic plasticity and motor learning circuits, suggesting dasatinib combined with robotic rehabilitation could enhance neuroplasticity during therapy while simultaneously reducing neuroinflammation.
Why Novel
Dasatinib has been explored in early Parkinson's research for its senolytic properties but never specifically for Src-mediated neuroinflammation blockade via this pathway. Zero studies combine Src inhibition with robotic rehabilitation despite Src's known role in synaptic plasticity that robotic therapy exploits. Extracellular vesicles propagating α-synuclein pathology represent another newly identified target — cannabinoids modulating EV cargo composition is completely unexplored.
Actionable Next Steps
In vitro: confirm dasatinib blocks the full CD11b/Src/Erk/NOX2 cascade in microglial cell lines exposed to paraquat. Animal study: dasatinib in PD mouse models measuring neuroinflammation markers, dopaminergic neuron survival and motor function. Phase I safety study of low-dose dasatinib in early PD patients measuring Src phosphorylation and inflammatory biomarkers. Parallel: pilot dasatinib + robotic gait training in 20 patients measuring motor outcomes.
Multiple Sclerosis39/50
Rituximab + tDCS Sequential Protocol for Inflammation Reduction and Remyelination
Rituximab + Transcranial Direct Current StimulationMay 16, 2026
B-cell depletion drugs like rituximab excel at preventing new MS lesions but cannot repair existing damage causing persistent motor and cognitive deficits. Transcranial direct current stimulation (tDCS) promotes remyelination through neuroplasticity mechanisms that address exactly this repair gap. Combining rituximab — which reduces inflammation — with tDCS — which promotes active repair — targets both disease processes simultaneously. This complementary combination has zero prior research despite the logic being immediately apparent.
Novel Mechanism
Rituximab depletes CD20+ B-cells, eliminating inflammatory B-cell activity and preventing new lesion formation. tDCS applies low electrical current to modulate cortical excitability, promoting long-term potentiation in damaged circuits and stimulating oligodendrocyte precursor cells toward remyelination. The sequential protocol — rituximab first to reduce inflammatory interference, then tDCS during the immunosuppressed window — exploits the B-cell depletion period as an optimal remyelination environment.
Why Novel
Current MS treatment operates on a prevention model — stopping new damage — while repair of existing damage remains largely unaddressed. Real-world data confirms rituximab matches purpose-built ocrelizumab for efficacy, suggesting mechanism matters more than antibody specificity. Yet zero studies have combined anti-CD20 therapy with any neuromodulation approach. The gap between inflammation suppression and active repair represents the most important unaddressed problem in MS.
Actionable Next Steps
Pilot study: 30 MS patients on stable rituximab receive 4-week tDCS protocol during B-cell nadir, measuring motor and cognitive outcomes vs. rituximab alone. MRI sub-study measuring myelin water fraction changes as remyelination biomarker. Optimal timing study: compare tDCS during B-cell nadir vs. pre-infusion vs. post-repopulation to identify the optimal treatment window. Modafinil + tDCS combination to amplify cortical excitability during stimulation.
Endometriosis36/50
Pexacerfont as Peripheral CRHR1 Antagonist for Endometriosis Pain
Pexacerfont + DienogestMay 25, 2026
Endometriosis pain is driven by a local estrogen→CRH→inflammation axis in ectopic lesions — independent of lesion burden. Pexacerfont, an oral CRHR1 antagonist with existing human safety data from anxiety/depression trials, blocks this peripheral pain pathway without suppressing ovarian function. Current treatments like GnRH analogs cause bone density loss and surgical menopause risk — pexacerfont avoids both entirely. Zero prior studies have connected pexacerfont to endometriosis despite a mechanistically perfect fit.
Novel Mechanism
Estrogen directly upregulates CRH expression in ectopic endometrial tissue, creating a local CRH→CRHR1 signalling axis on immune cells and nociceptors. This drives mast cell degranulation, pro-inflammatory cytokine release (IL-6, TNF-α) and direct nociceptor sensitisation — independently of systemic hormonal pathways. Pexacerfont selectively blocks peripheral CRHR1, interrupting this pain cascade at source without touching the HPA axis or ovarian function.
Why Novel
CRHR1 upregulation in ectopic endometrial lesions was only recently characterised, and pexacerfont was developed exclusively for CNS indications. The cross-disciplinary gap between stress neuroscience and gynaecological pain research means this connection has never been made. Unlike GnRH analogs which cause systemic estrogen suppression, pexacerfont targets the downstream inflammatory consequence — making it potentially compatible with fertility preservation and long-term use.
Actionable Next Steps
Tissue validation: measure CRHR1 expression and CRH levels in peritoneal fluid from endometriosis patients vs. controls. Pharmacokinetic study: confirm pexacerfont achieves therapeutically relevant concentrations in peritoneal tissue at oral doses. Pilot RCT: pexacerfont vs. placebo in 40 confirmed endometriosis patients over 3 months, primary endpoint VAS pain scores. Combination arm: pexacerfont + dienogest to test additive effect on both pain and adhesion formation.
Chronic Pain36/50
Ibudilast + TSPO-PET Imaging: First Neuroinflammation-Targeted Treatment for Central Sensitisation
Chronic pain's central sensitisation has an identifiable molecular substrate — microglial neuroinflammation visible on TSPO-PET imaging. Ibudilast, approved in Japan and Korea for asthma, crosses the blood-brain barrier and suppresses microglial TLR4-mediated inflammation. Zero trials have tested it in primary chronic pain despite a directly relevant mechanism and an available imaging biomarker to confirm target engagement — making it the first agent testable with a validated neuroinflammatory readout.
Novel Mechanism
Microglial TLR4 activation drives IL-1β and TNF-α release, amplifying central sensitisation in the spinal cord and supraspinal pain circuits. Ibudilast inhibits PDE4 and PDE10, suppressing this cascade while crossing the blood-brain barrier — confirmed in human trials for opioid dependence and progressive MS. TSPO is upregulated in activated microglia and is a validated PET target, meaning neuroinflammatory signal reduction can be tracked radiologically in real time. This creates a pharmacodynamic biomarker loop no chronic pain trial has ever used.
Why Novel
While microglial activation in chronic pain is well-documented, ibudilast has never been trialled in primary chronic pain syndromes (fibromyalgia, CRPS, neuropathic pain) despite phase II data in adjacent indications. The TSPO-PET pairing is the genuinely new layer — no published trial has used neuroinflammatory PET as a pharmacodynamic endpoint for a microglial inhibitor in non-cancer chronic pain. Additional candidates identified: minocycline (P2X4 purinergic blockade restoring GABAergic inhibition) and low-dose naltrexone (TLR4 antagonism at nanomolar concentrations) — both with zero trials in CRPS despite directly relevant mechanisms.
Actionable Next Steps
Phase II trial: ibudilast in fibromyalgia or CRPS patients with TSPO-PET imaging at baseline and 12 weeks, measuring neuroinflammatory signal reduction alongside pain scores. Ibudilast is already in human trials (opioid dependence, MS), so safety data and IND pathways exist. Parallel: low-dose naltrexone RCT in CRPS or hypermobility-associated pain — feasible within 12 months given off-patent status, oral administration and excellent safety profile. Minocycline + PRF combination study to simultaneously address peripheral input and central microglial amplification.
Lupus (SLE)36/50
Daratumumab for Refractory Lupus Nephritis: Targeting the CD20-Negative Plasma Cell Escape
Daratumumab (Anti-CD38)May 31, 2026
Rituximab fails in a significant subset of lupus nephritis patients — not because B-cell depletion is the wrong strategy, but because rituximab misses its target. Long-lived plasma cells in bone marrow niches are CD20-negative, meaning they survive rituximab and continue producing anti-dsDNA antibodies that drive nephritis. Daratumumab, FDA-approved for multiple myeloma, depletes these cells directly via CD38. This explains rituximab partial responses and identifies the precise patient population — persistent anti-dsDNA despite B-cell depletion — most likely to benefit.
Novel Mechanism
Long-lived plasma cells (LLPCs) reside in bone marrow niches and are CD20-negative but CD38-high. They are the source of persistent pathogenic autoantibodies — anti-dsDNA, anti-Sm, anti-phospholipid — that drive lupus nephritis, CNS disease and thrombosis. Rituximab depletes CD20+ B-cells and short-lived plasmablasts but leaves LLPCs intact, explaining why autoantibody titres often remain elevated post-treatment. Daratumumab deploys three independent cytotoxic mechanisms against CD38+ cells (ADCC, CDC, direct apoptosis induction) — the same validated mechanism from myeloma biology, now applied to the autoimmune plasma cell pool.
Why Novel
The mechanistic gap — that CD20-negative LLPCs escape rituximab and sustain autoantibody production — is established in the literature but has not yet reached standard clinical practice. A documented SLE case demonstrated daratumumab depleting plasma cells producing insulin receptor autoantibodies with complete clinical resolution, providing direct in-vivo proof of concept in SLE. Phase 3 RCT data also confirms dapirolizumab pegol efficacy via CD40L blockade, and orelabrutinib (BTK inhibitor) shows benefit in the IFN-high molecular SLE subtype — together supporting a molecularly stratified treatment approach that current practice does not employ.
Actionable Next Steps
Target population: refractory lupus nephritis patients with persistent anti-dsDNA titres despite rituximab or obinutuzumab — a measurable, identifiable cohort. Phase II endpoint design: LLPC depletion confirmed by bone marrow biopsy, serial anti-dsDNA titres, complement levels and renal function. Subcutaneous daratumumab formulation simplifies administration. Regulatory path: supplemental indication via Janssen or investigator-initiated trial with off-label use. Companion biomarker: baseline CD38+ LLPC burden as stratification tool.